皮内注射水通道蛋白 4 肽免疫诱导小鼠出现视神经脊髓炎谱系疾病的临床特征。

Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice.

机构信息

Product Research Department, Chugai Pharmaceutical Co., Ltd, Kanagawa, Japan.

出版信息

J Neuroimmunol. 2023 Jul 15;380:578109. doi: 10.1016/j.jneuroim.2023.578109. Epub 2023 May 16.

DOI:10.1016/j.jneuroim.2023.578109

Abstract

We challenged to create a mouse model of neuromyelitis optica spectrum disorder (NMOSD) induced by AQP4 peptide immunization. Intradermal immunization with AQP4 p201-220 peptide induced paralysis in C57BL/6J mice, but not in AQP4 KO mice. AQP4 peptide-immunized mice showed pathological features similar to NMOSD. Administration of anti-IL-6 receptor antibody (MR16-1) inhibited the induction of clinical signs and prevented the loss of GFAP/AQP4 and deposition of complement factors in AQP4 peptide-immunized mice. This novel experimental model may contribute to further understanding the pathogenesis of NMOSD, elucidating the mechanism of action of therapeutic agents, and developing new therapeutic approaches.

摘要

我们试图建立视神经脊髓炎谱系疾病（NMOSD）的 AQP4 肽免疫诱导的小鼠模型。AQP4 p201-220 肽皮内免疫可诱导 C57BL/6J 小鼠瘫痪，但不会诱导 AQP4 KO 小鼠瘫痪。AQP4 肽免疫的小鼠表现出类似于 NMOSD 的病理特征。抗白细胞介素 6 受体抗体（MR16-1）的给药抑制了临床症状的诱导，并防止了 AQP4 肽免疫的小鼠中 GFAP/AQP4 的丢失和补体因子的沉积。这种新的实验模型可能有助于进一步了解 NMOSD 的发病机制，阐明治疗药物的作用机制，并开发新的治疗方法。